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Background: Brain metastases (BMs) pose a clinical challenge in breast cancer (BC). Lapatinib or temozolomide
showed activity in BM. Our study assessed the combination of both drugs as treatment for patients with HER2-positive
BC and BM.
Methods: Eighteen patients were enrolled, with sixteen of them having recurrent or progressive BM. Any type of
previous therapy was allowed, and disease was assessed by gadolinium (Gd)-enhanced magnetic resonance imaging
(MRI). The primary end points were the evaluation of the dose-limiting toxicities (DLTs) and the determination of the
maximum-tolerated dose (MTD). The secondary end points included objective response rate, clinical beneﬁt and duration
of response.
Results: The lapatinib–temozolomide regimen showed a favorable toxicity proﬁle because the MTD could not be
reached. The most common adverse events (AEs) were fatigue, diarrhea and constipation. Disease stabilization was
achieved in 10 out of 15 assessable patients. The estimated median survival time for the 16 patients with BM reached
10.94 months (95% CI: 1.09–20.79), whereas the median progression-free survival time was 2.60 months [95%
conﬁdence interval (CI): 1.82–3.37].
Conclusions: The lapatinib–temozolomide combination is well tolerated. Preliminary evidence of clinical activity was
observed in a heavily pretreated population, as indicated by the volumetric reductions occurring in brain lesions.
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introduction
HER-2 overexpression is reported in ∼20% of breast cancer
(BC) patients, conferring aggressive biological [1, 2]. The
treatment of patients with HER2-positive BC has been
revolutionized by trastuzumab and lapatinib [3].
Brain metastatic dissemination remains an unresolved medical
need, with BC being the second most common cause of brain
metastases (BM) [4]. HER-2 positivity is a risk factor for BM in
patients diagnosed with BC [5], with evidence supporting that
trastuzumab-treated HER2 overexpressing metastatic BC bear an
increased risk for BM [6]. The reasons for this are debatable:
trastuzumab does not fully penetrate the intact blood–brain
barrier (BBB), thus sparring cancer cells in the central nervous
system (CNS) [7]. Alternatively, its high efﬁcacy in controlling
extracranial disease prolongs overall survival, turning the brain
into a ‘sanctuary’ for metastatic disease [8].
Standard therapeutic options for BM include local
approaches such as neurosurgical resection, stereotactic
radiosurgery (SRS) and whole brain radiation therapy (WBRT),
with the role of systemic therapy being unclear.
Lapatinib as a small-molecule inhibitor can penetrate more
efﬁciently the BBB [9]. Moreover, the lack of cross-resistance
with trastuzumab promises efﬁcacy in trastuzumab-pretreated
patients [10–13].
Temozolomide is an alkylating agent, which has a lipophilic
structure enabling BBB penetration. It has been tested in BM
from different tumors either alone or in combination with
capecitabine showing some activity [14–16].†EDA and DZ contributed equally to this work.
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In our trial (NCT00614978), we studied the combination of
lapatinib and temozolomide in patients with HER2-positive BC
presenting BM.
materials andmethods
eligibility
This study was conducted at the Jules Bordet Institute (IJB), Brussels,
Belgium. All patients enrolled received lapatinib combined with
temozolomide. Eligibility criteria are published online only.
study design
This was an open-label phase I study. The primary end point was to evaluate
the dose-limiting toxicities (DLTs) and determine the maximum-tolerated
dose (MTD) of lapatinib plus temozolomide (supplementary Table S1,
available at Annals of Oncology online). The secondary end point was to
evaluate their clinical activity.
Three to six subjects were enrolled in ﬁve dose cohorts (supplementary
Table S2, available at Annals of Oncology online), with dose escalation
following the classical ‘3 + 3’ phase I trial design.
treatment planning
Temozolomide was given orally, once a day, at three dose levels: 100, 150
and 200 mg/m2/day, days 1–5. Lapatinib was given orally, once a day at three
dose levels: 1000, 1250, 1500 mg/day. Both agents were given until
progression of the disease, intolerable toxicity or a maximum of six cycles,
whichever came ﬁrst. A cycle was deﬁned as 28 days of therapy.
response assessments
Brain magnetic resonance imagings (MRIs) were obtained at study entry and
every 8 weeks thereafter. They included volumetric, 3D-gradient echo
T1-weighted images, before and 10–15 min after intravenous administration
of Gd at a dose of 0.1 mmol/Kg body weight. The image assessments, carried
out at IJB, were reviewed by one expert radiologist (ML) using both 2D
measurement of the longest axial diameters and 3D volumetric
measurement of the lesions using 3D segmentation software (VOXAR 3D®
from Toshiba Medical Systems). A CNS objective response was deﬁned as
either a complete response (CR: disappearance of all target lesions) or a
partial response (PR: at least a 30% decrease in the sum of the longest
diameter of the target lesions). Progressive disease (PD) was deﬁned as the
occurrence of either a new lesion or a >20% increase in the sum of the
longest diameter of the target lesions. Stable disease (SD) was deﬁned as
neither sufﬁcient shrinkage to qualify for PR nor sufﬁcient increase to
qualify for PD, taking as a reference point the smallest sum of the longest
diameter since the treatment started.
Treatment response outside of the CNS was evaluated by the investigator
according to the Response Evaluation Criteria in Solid Tumors (RECIST,
Version 1.0) guidelines, but was not mandatory as per protocol and was
carried out by the investigator as part of the patient’s standard of care.
safety assessments
In the present study, adverse events (AEs) and/or adverse drug reactions
were recorded according to the National Cancer Institute Common
Terminology Criteria for Adverse Events version 3.0 (NCI CTCAE v3.0).
Cardiac monitoring was carried out, with an LVEF assessment using either
ECHO or MUGA scan at baseline and every 12 weeks thereafter.
statistical analysis
The study’s sample size was determined according to the well-established
current methodology used to design dose-ﬁnding studies in oncology (‘3 + 3’
design). The ‘safety analyses set’ of subjects consisted of all patients who
received at least one dose of lapatinib and temozolomide. AEs were listed by
cohort/dose-level and evaluation time point using descriptive statistics. The
‘efﬁcacy analysis set’ of participants included all eligible patients who had
received at least 28 days of therapy and who had at least one post-therapeutic
assessment of disease status by MRI. The efﬁcacy end points are listed per
dose level and cycle using descriptive statistics.
results
patients
Eighteen HER2-positive metastatic BC patients were enrolled
between January 2008 and May 2011. Demographic and clinical
characteristics are displayed in Table 1. Sixteen patients showed
at least one BM but, because of slow study accrual, two patients
with no BM and no standard therapeutic options available were
enrolled.
The median age of all patients was 50 years (range, 34–77
years). This was a heavily pretreated population, with a median
of four prior regimens (range, 1–7).
Regarding CNS disease, all but three patients had received
prior CNS irradiation, and one had received additionally SRS.
Sixteen patients had multiple BM, whereas one patient started
the study treatment before SRS. The distribution of patients
according to the treatment dose levels is shown in
Supplementary Table S2, available at Annals of Oncology online.
The median treatment duration reached 64 days (range, 23–169
days), with a median of two cycles (range, one to six cycles). The
study drugs were stopped because of disease progression
(n = 14), AEs (n = 3) and death (n = 1).
side effects
The non-hematologic toxicity was mainly grade 2 or higher
(Table 2), with the most common AEs being fatigue, diarrhea
and constipation. The following grade 3 AEs were observed:
diarrhea in one patient at dose level I resulting in treatment
discontinuation; fatigue in three patients at dose levels I, III and
V, respectively; an infection (port-a-cath associated bacteremia)
in one patient at dose level IV resulting in study withdrawal;
bacterial pneumonia in one patient at dose level V; nausea in
one patient at dose level V, which was managed with
medication.
Few hematologic AEs were reported (Table 2), with no
neutropenic fever. Per protocol deﬁnition, the MTD was not
reached and both agents can be administered combined fully
dosed. One patient developed grade 3 thrombocytopenia while
on her ﬁrst cycle at dose level V, with no major bleeding event.
However, the treatment was delayed for 2 weeks, which
constituted the only DLT observed. After the ﬁrst cycle, this
patient developed combined grade 4 leukopenia/neutropenia,
not constituting a DLT (duration <7 days).
In terms of cardiac safety, no major toxicity events were
observed. Nine patients underwent a second cardiac monitoring
at 12 weeks. None of them showed an LVEF <50% or an
absolute LVEF drop >15%.
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tumor response
Evaluation of response using volumetric brain MRI was a
secondary end point. Two patients did not have BM at baseline;
a third patient received one cycle of treatment and stopped
because of clinical PD. For the 15 remaining assessable patients,
SD was achieved in 10 patients (67%) and PD in 5 patients
(33%). The best response was in each case achieved after two or
three cycles (one patient with SD was not assessed beyond two
cycles).
The analysis of volumetric changes from the largest brain
lesion was carried out in 13 patients (Figure 1A). Five patients
out of the 18 were non-assessable for the purposes of this
analysis: two had no BM at baseline, one had no reported
volume at baseline and two had no measurements after baseline.
For the same cohort of 13 patients, a separate volumetric
changes analysis was undertaken using the sum of the
volumetric measures of all lesions as calculated at baseline and
at the follow-up brain MRI (Figure 1B). The relative evolution
from baseline was calculated and the largest reduction was
selected.
Table 1. Patient characteristics
Characteristic No of patients %
Age, years
Median 50
Range 34–77
ECOG performance status
0 1 6
1 16 89
2 1 6
Hormone receptor status from primary tumor
Positive 10 56
Negative 8 44
No. of metastatic sites of disease
Median 2
Range 1–3
Sites of disease
Brain 16 89
Lung 5 28
Liver 4 22
Nodes 4 22
Bone 2 11
Pleura 2 11
Adrenals 1 6
Peritoneum 1 6
Prior chemotherapy regimens (with or without biological agents)
Median 4
Range 1–7
Median time to recurrence and brain metastasis (months, range)
Median time to recurrence 38.5 (0.0–163.1)
Median time to brain metastasis 60.8 (4.2–265.3)
Prior chemotherapy regimens (with biological agents)
Median 1
Range 0–3
Prior biological agents without chemotherapy
Median 1
Range 0–2
Prior exposure to speciﬁc agents
Trastuzumab 18 100
Anthracycline 18 100
Taxane 17 94
Capecitabine 12 67
Lapatinib 8 44
Vinorelbine 7 39
Platinum derivative 6 33
Prior CNS irradiation
None 3 17
WBRT only 14 78
SRS only 0 0
WBRT and SRS 1 6
ECOG, Eastern Cooperative Oncology Group; SRS, stereotactic radiosurgery;
WBRT, whole brain radiotherapy.
Table 2. Toxicity by frequency
Adverse event Grade 1 Grade 2 Grade 3 Grade 4 Total
number
of patients
Non-hematologic toxicity
Fatigue 6 5 3 – 14
Diarrhea 5 3 1 – 9
Constipation 7 1 – – 8
Anorexia 2 3 – – 5
Headache 4 1 – – 5
Vertigo 4 1 – – 5
Nausea 3 – 1 – 4
Neuropathy 4 – – – 4
Vomiting 4 – – – 4
Abdominal pain 3 – – – 3
Articular pain 3 – – – 3
Dry skin 2 1 – – 3
Dyspnea 3 – – – 3
Infection 1 – 1 – 2
Muscular pain 2 – – – 2
Cholestasis 1 – – – 1
Cognitive
disturbance
1 – – – 1
Diabetes
exacerbation
– 1 – – 1
Dry mouth 1 – – – 1
Dysphagia – 1 – – 1
Epistaxis 1 – – – 1
Hyponatremia 1 – – – 1
Liver enzymes
elevation
1 – – – 1
Pneumonia – – 1 – 1
Pleural effusion – 1 – – 1
Rash 1 – – – 1
Seizure – 1 – – 1
Stomatitis 1 – – – 1
Vision disturbances 2 – – – 2
Hematologic toxicity
Anemia 6 – – – 6
Leukopenia 4 1 – 1 6
Neutropenia – – 1 1 2
Thrombocytopenia 4 – 1 – 5
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Overall, as of 31 May 2012, all 18 patients experienced tumor
progression. The estimated median progression-free survival
was 2.60 months [95% conﬁdence interval (CI): 1.78–3.42] for
all 18 patients. It was also 2.60 months (95% CI: 1.82–3.37) for
the 16 patients with BM. Death occurred in 14 patients, which
corresponded to an estimated median survival time of 10.9
months (95% CI: 2.5–19.3) for all 18 patients, and 10.94 months
(95% CI: 1.09–20.79) for the 16 patients with BM.
In terms of extracranial disease assessment, three patients
showed SD of the brain but experienced extracranial PD after
two, three and six cycles of treatment, respectively. Regarding
the two patients without BM at study entry, one received six
cycles and the other one cycle of the study treatment.
Unfortunately, both the patients experienced systemic PD.
However, the former of these latter two patients initially showed
a metabolic PR of intrahepatic metastases on a PET scan.
discussion
This phase I study evaluated the safety of lapatinib combined
with temozolomide in patients with HER2-positive BC and BM.
This combination was found to be well tolerable.
Fatigue, diarrhea and constipation were the most frequent
AEs. Hematologic toxicity was not frequent, and no cases of
neutropenic fever or need for transfusions were reported. No
cardiac toxicity was observed in assessable patients.
Preliminary efﬁcacy data were generated in our study, with 10
out of 15 assessable patients achieving a SD (67%). The
volumetric analyses carried out either for the sum of all BM or
for the largest lesion indicated reductions in size, suggesting
clinical beneﬁt. With heavily pretreated patients in this study,
including lapatinib pretreatment, it is conceivable that this
element masked the efﬁcacy of our regimen. Furthermore, all
but one patient with BM had undergone local treatment
consisting of WBRT and/or SRS.
Putting our trial in context with other relevant studies, we
noted that in a retrospective analysis of patients treated with
lapatinib combined with capecitabine, seven PRs were reported
for BM, with three of these PRs achieved in the absence of prior
local treatment [17]. Building on that concept, the
LANDSCAPE trial assessed the use of lapatinib plus
capecitabine before WBRT and found this to be an alternative to
WBRT as front-line treatment [18]. Such an approach could
substantially improve the quality of life of patients with BM by
postponing the WBRT-induced cognitive deﬁcit [19]. The
results of the randomized phase III CEREBEL study, comparing
the incidence of BM in patients with HER2-positive metastatic
BC treated with lapatinib plus capecitabine versus trastuzumab
plus capecitabine, have been presented [20]. CEREBEL did not
show a decrease of the incidence of BM as site of ﬁrst relapse for
patients treated with the lapatinib–capecitabine compared with
trastuzumab–capecitabine (8 versus 12 cases, P = 0.360). These
results must be interpreted with caution, because the incidence
of BM as the ﬁrst site of progression in both arms was low [21].
WBRT combined with systemic treatment could be another
approach, analogous to a trial in which WBRT was administered
with a protracted low dose of oral vinorelbine and
temozolomide in BC patients with newly diagnosed BM [22].
Out of 36 patients, 3 CRs and 16 PRs were reported (ORR of
52%), with a favorable toxicity proﬁle. The advantage here is
mainly that WBRT disrupts the BBB, thus potentiating a higher
penetration of the systemic treatment in the brain [23]. Closely
monitoring the dosing of the systemic agents to avoid excessive
toxicity is essential.
Our study has some limitations such as the absence of
neurocognitive function evaluation. However, our patient
population was almost uniformly exposed to WBRT, and thus
Figure 1. (A) Best relative volumetric change in the largest brain metastasis
when compared with baseline. Each bar represents a patient having received
a baseline and at least an 8-week volumetric brain magnetic resonance
imaging (MRI) evaluation. Patients in red are those with progression as best
response. The vertical y-axis represents a relative reduction in the largest
brain metastasis (vol after treatment –Vol at baseline)/vol at baseline, with
negativity corresponding to a reduction and positivity corresponding to an
increase in the volume of the lesion. (B) Best relative volumetric change in
the sum of the volumetric measures of all brain lesions. Each bar represents
a patient having received a baseline and at least an 8-week volumetric brain
MRI evaluation. Patients in red are those with progression as best response.
The vertical y-axis represents a relative reduction in the sum of the
volumetric measures of all brain lesions (sum vol after treatment – sum vol
at baseline)/sum vol at baseline, with negativity corresponding to a
reduction and positivity corresponding to an increase in the sum of the
volumetric lesions.
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the chance that the patients had already developed
neurocognitive deﬁcits is high. The volumetric changes analysis
we undertook should be interpreted as exploratory, since no
clinically meaningful thresholds for tumor reduction exist.
However, in other trials volumetric reduction of CNS lesions
has been associated with clinical beneﬁt [11, 24].
In summary, this study proves the feasibility of treating
patients with BM originating from HER2-positive BC with the
combination of lapatinib and temozolomide at their single-
agent recommended doses. Volumetric reductions in BM were
also achieved. However, the lack of objective responses suggests
limited antitumor activity of the regimen in this heavily
pretreated population.
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